$CNTA News

Wells Fargo Downgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $42

Guggenheim Downgrades Centessa Pharmaceuticals to Neutral

Leerink Partners Downgrades Centessa Pharmaceuticals to Market Perform, Raises Price Target to $40

Eli Lilly's Centessa Deal Shows It Is Awake To New Narcolepsy Reality

Wolfe Research Downgrades Centessa Pharmaceuticals to Peer Perform

Needham Downgrades Centessa Pharmaceuticals to Hold

Centessa Pharmaceuticals shares are trading higher after the company announced that it will be acquired by Eli Lilly for as much as $47 per share.

Centessa Pharmaceuticals shares are trading higher after the company announced that it will be acquired by Eli Lilly for as much as $47 per share.

Wolfe Research Initiates Coverage On Centessa Pharmaceuticals with Outperform Rating, Announces Price Target of $40

Truist Securities Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $38

Centessa Pharmaceuticals Reveals Poster Presentation Of New Preclinical Data Supporting Expansion of Orexin Receptor 2 Agonist Pipeline Into Neuropsychiatric Indications At The 64th ACNP Annual Meeting

Truist Securities Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $33

Praxis tees up another approval filing; Geron turns to layoffs

Centessa Pharmaceuticals (CNTA): Revisiting Valuation After Strong ORX750 Phase 2 Data and Leadership Shift

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals Names Orexin Program Founder Mario Accardi As Chief Executive Officer Effective January 1 2026 As Company Advances OX2R Agonist Pipeline Including ORX750 Toward Q1 2026 Registrational Program

Oppenheimer Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $62

Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results

B. Riley Securities Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $42

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company